KRAS and non-small cell lung carcinoma: Despite the encouraging results observed in the treatment of patients with KRAS-G12C-mutant NSCLC, both initial and acquired resistance can limit the efficacy of targeted therapies, as observed in EGFR-mutant NSCLC and ALK-translocated NSCLC.8